Sarah Cannon Research Institute’s Post

"Combining standard 4-6 cycles of chemotherapy with immune checkpoints inhibitors has shown to improve survival in patients with non-small cell lung cancer (NSCLC), however increased toxicities have also been reported. Here the authors report the results of a phase 2 trial of sintilimab (anti-PD1) with two cycles of chemotherapy for treatment of previously untreated advanced squamous NSCLC." "sintilimab in combination with 2 cycles of nab-paclitaxel/carboplatin treatment produced encouraging PFS and better tolerability as first-line treatment for advanced sq-NSCLC." https://lnkd.in/eQeM6aa3

Encouraging development in Lung Cancer Treatment R&D Positive top-line results from a late-stage study of Eli Lilly's targeted therapy Retevmo (selpercatinib) - evaluated against the current first-line standard of care in certain non-small cell lung cancer (NSCLC) patients. The phase 3 LIBRETTO-431 clinical trial evaluated Retevmo against platinum-based chemotherapy plus pemetrexed with or without Merck’s Keytruda (pembrolizumab) - as an initial treatment for adults with rearranged during transfection (RET) fusion-positive advanced or metastatic NSCLC.

Busy news day today, so this might fly under your radar: Merck's Keytruda makes progress toward earlier stages of cervical cancer with new Phase III data, showing that it improves overall survival in this indication. Friday's readout comes after the pharma announced last year that Keytruda also significantly benefits PFS in these patients. Keytruda already has two approved indications in cervical cancer. The first is as a combo treatment with chemotherapy, with or without Roche’s Avastin (bevacizumab), for the treatment of persistent, recurrent or metastatic disease. The second is as a monotherapy for metastatic or recurrent cervical cancer that has progressed following chemotherapy. #biotech #biopharma #Keytruda #cervicalcancer

🎗️🧫Another significant development in targeted therapy - this one for HER2-positive tumor types. Although HER2-positive appendiceal tumors are very rare, this development is (1) a demonstration of the evolution of cancer treatments more broadly; and (2) a welcome addition to treatment options for any patient who happens to have HER2-positive appendiceal cancer. https://lnkd.in/eG5fAdj7

Exciting advancements in cancer treatment continue to shape the industry landscape. Antibody-drug conjugates (ADCs) are at the forefront, revolutionizing targeted therapies for cancer patients. By combining specific antibodies with cytotoxic drugs, ADCs precisely target cancer cells, sparing healthy cells and minimizing side effects. This innovative approach offers a more precise and potentially less harmful treatment option compared to traditional chemotherapy. Stay informed on this cutting-edge topic with a quick-hit article I discovered. #CancerResearch #MedicalAdvancements #HealthcareInnovation

AstraZeneca announced Tuesday that its PD-L1 inhibitor Imfinzi (durvalumab) did not meet its primary endpoint in the Phase III ADJUVANT BR.31 study in early stage non-small cell lung cancer. Without revealing specific data, AstraZeneca said that Imfinzi was unable to significantly improve disease-free survival versus placebo in patients with stage IB to IIIA non-small cell lung cancer (NSCLC) following complete tumor resection. Meanwhile, the pharma on Tuesday also reported that Imfinzi cleared the Phase III NIAGARA study in muscle-invasive bladder cancer (MIBC). The PD-1 inhibitor, when combined with chemotherapy, induced a “statistically significant and clinically meaningful improvement” in event-free and overall survival as compared with neoadjuvant chemotherapy. #biotech #biopharma #NSCLC #bladdercancer #Imfinzi

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1 https://lnkd.in/dN2z_cSe

🏆 We are thrilled to share a groundbreaking development in the fight against cancer. Iovance has received US FDA accelerated approval for AMTAGEV™ (lifileucel), marking a significant milestone in cancer treatment options. 🙌 This advancement underscores our commitment to innovation and providing hope to patients facing cancer. Lifileucel represents a pivotal step forward in personalized medicine, offering a new avenue of hope for those in need. 💪 Stay informed by following us about this incredible breakthrough and how it's setting new standards in cancer care. Click the link to read the full press release 👇 Let's embrace the future of cancer therapy together! #CancerResearch #InnovationInHealth #PersonalizedMedicine #FDAApproval #Iovance #CellTherapy #CellTherapyManufacturing

As we look toward the horizon of cancer therapy, Radionuclide Drug Conjugates (RDCs) could play an important role in the personalization of treatment. By harnessing the power of targeted therapy, RDCs offer a glimpse into a future where cancer treatment is not only effective but also tailored to the individual needs. In this article, we talked about how RDCs might revolutionize cancer treatment. https://hubs.li/Q02xMM800 #OncologyInnovation #nuclearmedicine #radiopharmaceuticals #CancerTreatment #DMPK #drugdiscovery #drugdevelopment